Edition:
United Kingdom

Nippon Shinyaku Co Ltd (4516.T)

4516.T on Tokyo Stock Exchange

8,040JPY
4:24am GMT
Change (% chg)

¥20 (+0.25%)
Prev Close
¥8,020
Open
¥7,980
Day's High
¥8,090
Day's Low
¥7,910
Volume
86,400
Avg. Vol
198,150
52-wk High
¥8,210
52-wk Low
¥5,160

Latest Key Developments (Source: Significant Developments)

Actelion wins Swiss approval of uptravi for form of high blood pressure
Tuesday, 16 Aug 2016 

Actelion Ltd : Says receives Swissmedic approval for uptravi (selexipag) for treatment of pulmonary arterial hypertension .Swissmedic has granted approval for orally active originally discovered and synthesized by Nippon Shinyaku, for patients with PAH in Switzerland.  Full Article

Nippon Shinyaku gets marketing approval of Uptravi in EU
Tuesday, 17 May 2016 

Nippon Shinyaku Co Ltd <4516.T> : Says the company obtained the marketing approval of Uptravi in EU on May 12 .Says Uptravi is a medicine for the treatment of hypertension.  Full Article

Nippon Shinyaku to start phase 2 clinical study of NS-065
Wednesday, 30 Mar 2016 

Nippon Shinyaku Co Ltd:Submitted to the Food and Drug Administration (FDA) on March 25, 2016, an Investigational New Drug (IND) Application for a phase 2 clinical study of NS-065, the first antisense oligonucleotide discovered in Japan for the treatment of Duchenne Muscular Dystrophy (DMD).  Full Article